Image 01 Image 02 Image 03


Novavax might give America its fourth COVID-19 vaccine after a trial showed it is 90.4% overall efficient. The vaccine also protects people from moderate and severe COVID-19 in the PREVENT-19 Phase 3 trial.

Pfizer and BioNTech found its COVID-19 is 95% effective in the last trial run, "meeting all primary efficacy endpoints." The vaccine also showed signs of safety and met all the requirements for the FDA to approve its use as soon as possible.